Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators

  title={Nootropic $\alpha$7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators},
  author={Herman J Ng and Edward R. Whittemore and Minhtam B. Tran and Derk J. Hogenkamp and Ron S. Broide and Timothy B C Johnstone and Lijun Zheng and Karen E. Stevens and Kelvin W. Gee},
  journal={Proceedings of the National Academy of Sciences},
  pages={8059 - 8064}
Activation of brain α7 nicotinic acetylcholine receptors (α7 nAChRs) has broad therapeutic potential in CNS diseases related to cognitive dysfunction, including Alzheimer's disease and schizophrenia. In contrast to direct agonist activation, positive allosteric modulation of α7 nAChRs would deliver the clinically validated benefits of allosterism to these indications. We have generated a selective α7 nAChR-positive allosteric modulator (PAM) from a library of GABAA receptor PAMs. Compound 6 (N… 

Figures from this paper

Pharmacological Characterization of the Novel and Selective α7 Nicotinic Acetylcholine Receptor–Positive Allosteric Modulator BNC375
Systemic administration of BNC375 reverses scopolamine-induced cognitive deficits in rat novel object recognition and rhesus monkey object retrieval detour task over a wide range of exposures, showing no evidence of an inverted U-shaped dose-effect curve and suggesting that α7 nAChR PAMs have therapeutic potential in central nervous system diseases with cognitive impairments.
An Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in Vivo
Data support the notion that α7 nAChR allosteric modulation may constitute a novel pharmacological principle for the treatment of cognitive dysfunction.
Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site
These findings suggest that the transmembrane regions of α7 are a conserved modulatory allosteric site within neurotransmitter-gated ion channels, much as neurosteroids and volatile anesthetics are thought to interact with GABAA and glycine receptors.
Characterization of RO5126946, a Novel α7 Nicotinic Acetylcholine Receptor–Positive Allosteric Modulator
Overall, RO5126946 is a novel α7nAChR PAM with cognitive-enhancing properties that improves associative learning in a scopolamine-induced deficit model of fear conditioning in rats and is orally bioavailable and brain-penetrant.
Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats
Results support the use of α7 nAChR positive allosteric modulators as a potential treatment strategy in schizophrenia by demonstrating a beneficial effect on sensorimotor gating and some aspects of cognition tested in a rat model of schizophrenia.
Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Recent development of selective agonists and positive allosteric modulators of alpha7 nAChRs are discussed and the association between CHRNA7 gene and impaired P50 auditory gating has provided an attractive endophenotype.


A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In Vitro and In Vivo Characterization
Systemic administration of PNU-120596 to rats improved the auditory gating deficit caused by amphetamine, a model proposed to reflect a circuit level disturbance associated with schizophrenia, and has the potential to treat psychiatric and neurological disorders.
Selective α7 Nicotinic Acetylcholine Receptor Ligands
The structure and function of the α7 nAChR and its in vitro and in vivo pharmacology are described, the clinical relevance of these efforts are discussed, and the current progress in α7 ligand development is reviewed.
Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease
  • A. Maelicke
  • Biology, Medicine
    Dementia and Geriatric Cognitive Disorders
  • 2000
Allosteric modulation of nAChR is a novel approach, which circumvents the development of tolerance and could produce significant therapeutic benefit in AD.
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
An alpha7 nicotinic agonist appears to have positive effects on neurocognition in persons with schizophrenia, and significant neurocognitive improvement was found on the Repeatable Battery for the Assessment of Neuropsychological Status total scale score.
Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors
These studies support the previous proposal that the therapeutic action of galantamine is mainly produced by its sensitizing action on nAChRs rather than by general cholinergic enhancement due to cholinesterase inhibition.
An α7 Nicotinic Acetylcholine Receptor Gain-of-Function Mutant That Retains Pharmacological Fidelity
This article reports that an α7 T245S mutant, which has a point mutation at the sixth position in the α7 second transmembrane domain (T6′S), demonstrates a significant gain of function, sustaining current when exposed to relatively high agonist concentrations when expressed in Xenopus laevis oocytes and larger peak currents when expressing in mammalian GH4C1 cells.
Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons
The selective action of choline on native α7 nAChRs suggests that this naturally occurring compound may act in vivo as an endogenous ligand for these receptors.
Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia
Alpha-7 nicotinic receptor agonists appear to be reasonable candidates for the treatment of cognitive and perceptual disturbances in schizophrenia.
Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity
Galantamine enhances human α7 neuronal nicotinic ACh receptor activity and enhances muscular AChRs and the size of spontaneous cholinergic synaptic events, however, only a very narrow range of galantamine concentrations can be used for enhancing effects.
α7 Neuronal Nicotinic Acetylcholine Receptors Are Negatively Regulated by Tyrosine Phosphorylation and Src-Family Kinases
Examination of intracellular mechanisms by combining molecular biology, biochemistry, and electrophysiology in SH-SY5Y neuroblastoma cells, Xenopus oocytes, rat hippocampal interneurons, and neurons from the supraoptic nucleus finds tyrosine phosphorylation of α7 nAChRs, revealing novel regulatory mechanisms that may help to understand nicotinic receptor-dependent plasticity, addiction, and pathology.